First Header Logo Second Header Logo

Connection

Martha Alexander-Miller to T-Lymphocytes, Cytotoxic

This is a "connection" page, showing publications Martha Alexander-Miller has written about T-Lymphocytes, Cytotoxic.
  1. Holbrook BC, Yammani RD, Blevins LK, Alexander-Miller MA. In vivo modulation of avidity in highly sensitive CD8(+) effector T cells following viral infection. Viral Immunol. 2013 Oct; 26(5):302-13.
    View in: PubMed
    Score: 0.449
  2. Sharma SK, Alexander-Miller MA. Increased sensitivity to antigen in high avidity CD8(+) T cells results from augmented membrane proximal T-cell receptor signal transduction. Immunology. 2011 Jul; 133(3):307-17.
    View in: PubMed
    Score: 0.382
  3. Kroger CJ, Amoah S, Alexander-Miller MA. Cutting edge: Dendritic cells prime a high avidity CTL response independent of the level of presented antigen. J Immunol. 2008 May 01; 180(9):5784-8.
    View in: PubMed
    Score: 0.311
  4. Kroger CJ, Alexander-Miller MA. Dose-dependent modulation of CD8 and functional avidity as a result of peptide encounter. Immunology. 2007 Oct; 122(2):167-78.
    View in: PubMed
    Score: 0.290
  5. Cawthon AG, Alexander-Miller MA. Optimal colocalization of TCR and CD8 as a novel mechanism for the control of functional avidity. J Immunol. 2002 Oct 01; 169(7):3492-8.
    View in: PubMed
    Score: 0.211
  6. Parks GD, Alexander-Miller MA. High avidity cytotoxic T lymphocytes to a foreign antigen are efficiently activated following immunization with a recombinant paramyxovirus, simian virus 5. J Gen Virol. 2002 May; 83(Pt 5):1167-1172.
    View in: PubMed
    Score: 0.205
  7. Gray PM, Parks GD, Alexander-Miller MA. A novel CD8-independent high-avidity cytotoxic T-lymphocyte response directed against an epitope in the phosphoprotein of the paramyxovirus simian virus 5. J Virol. 2001 Nov; 75(21):10065-72.
    View in: PubMed
    Score: 0.198
  8. Cawthon AG, Lu H, Alexander-Miller MA. Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8alphabeta versus CD8alphaalpha expression. J Immunol. 2001 Sep 01; 167(5):2577-84.
    View in: PubMed
    Score: 0.196
  9. Alexander-Miller MA. Differential expansion and survival of high and low avidity cytotoxic T cell populations during the immune response to a viral infection. Cell Immunol. 2000 Apr 10; 201(1):58-62.
    View in: PubMed
    Score: 0.178
  10. Alexander-Miller MA, Derby MA, Sarin A, Henkart PA, Berzofsky JA. Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes. J Exp Med. 1998 Oct 19; 188(8):1391-9.
    View in: PubMed
    Score: 0.160
  11. Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med. 1996 Aug 01; 184(2):485-92.
    View in: PubMed
    Score: 0.138
  12. Alexander-Miller MA, Parker KC, Tsukui T, Pendleton CD, Coligan JE, Berzofsky JA. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes. Int Immunol. 1996 May; 8(5):641-9.
    View in: PubMed
    Score: 0.135
  13. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A. 1996 Apr 30; 93(9):4102-7.
    View in: PubMed
    Score: 0.135
  14. Alexander-Miller MA, Burke K, Koszinowski UH, Hansen TH, Connolly JM. Alloreactive cytotoxic T lymphocytes generated in the presence of viral-derived peptides show exquisite peptide and MHC specificity. J Immunol. 1993 Jul 01; 151(1):1-10.
    View in: PubMed
    Score: 0.111
  15. Alexander MA, Damico CA, Wieties KM, Hansen TH, Connolly JM. Correlation between CD8 dependency and determinant density using peptide-induced, Ld-restricted cytotoxic T lymphocytes. J Exp Med. 1991 Apr 01; 173(4):849-58.
    View in: PubMed
    Score: 0.095
  16. Snyder JT, Alexander-Miller MA, Berzofskyl JA, Belyakov IM. Molecular mechanisms and biological significance of CTL avidity. Curr HIV Res. 2003 Jul; 1(3):287-94.
    View in: PubMed
    Score: 0.056
  17. Spolski RJ, Alexander-Miller MA, Kuhn RE. Suppressed cytotoxic T lymphocyte responses in experimental cysticercosis. Vet Parasitol. 2002 Jul 02; 106(4):325-30.
    View in: PubMed
    Score: 0.052
  18. Leggatt GR, Alexander-Miller MA, Kumar A, Hoffman SL, Berzofsky JA. Cytotoxic T lymphocyte (CTL) adherence assay (CAA): a non-radioactive assay for murine CTL recognition of peptide-MHC class I complexes. J Immunol Methods. 1997 Feb 14; 201(1):1-10.
    View in: PubMed
    Score: 0.036
  19. Sarin A, Williams MS, Alexander-Miller MA, Berzofsky JA, Zacharchuk CM, Henkart PA. Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family proteases. Immunity. 1997 Feb; 6(2):209-15.
    View in: PubMed
    Score: 0.036
  20. Solheim JC, Alexander-Miller MA, Martinko JM, Connolly JM. Biased T cell receptor usage by Ld-restricted, tum- peptide-specific cytotoxic T lymphocyte clones. J Immunol. 1993 Feb 01; 150(3):800-11.
    View in: PubMed
    Score: 0.027
  21. Goss JA, Alexander-Miller MA, Gorka J, Flye MW, Connolly JM, Hansen TH. Specific prolongation of allograft survival by a T-cell-receptor-derived peptide. Proc Natl Acad Sci U S A. 1993 Nov 01; 90(21):9872-6.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.